Details:
Under the collaboration, Sanofi exercised one option to license a new ANKET® (antibody-based NK cell engager therapeutics) platform from Innate, for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.
Lead Product(s): Antibody-based NK Cell Engager Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,483.0 million Upfront Cash: $26.6 million
Deal Type: Licensing Agreement December 19, 2023
Details:
Through the acquisition, Eli lilly expands its portfolio of antibody-drug conjugates for cancer by gaining Mablink’s existing pipeline and proprietary PSARLink™ technology, an innovative hydrophilic linker which holds potential for broadening the therapeutic index of ADCs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 18, 2023
Details:
Under the termination, Transgene will regain the global rights to the intravenous oncolytic virus drug candidate, developed using Transgene’s next-generation viral Invir.IO™ platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 05, 2023
Details:
The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Oncode Bridge Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding February 08, 2022
Details:
The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center.
Lead Product(s): CAR-T Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Casdin Capital
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2021